LATEST ARTICLES

Missing Immune Cells Could Fight Glioblastoma

Glioblastoma, also known as glioblastoma multiforme, an aggressive type of cancer that can occur in the brain or spinal cord, can have an unusual effect on the body’s immune...

Cancer Research Organizations Recommend Changes to Reduce Barriers to Clinical Trial Participation

Two cancer research organizations, the American Society of Clinical Oncology, also known as ASCO® and Friends of Cancer Research have submitted to the U.S. Food and Drug Administration (FDA)...

Cory Wiegert Named New CEO of ASCO’s CancerLinQ

Cory Wiegert has been named Chief Executive Officer of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO), established for the development and...

Study Suggests Palliative Care Reduces Incidences of Suicide in Veterans with Lung Cancer

Results from a large-scale patient population study, supported by the National Cancer Institute of the National Institutes of Health, which was recently published in the Annals of the American...

First-Ever U.S. Guidelines for Gestational Trophoblastic Neoplasia Ensures Life-saving Treatmentnt

The National Comprehensive Cancer Network®, also known as NCCN®, a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, has released new treatment guidelines...

Phase III Trial of Anti-PD-1 Antibody Tislelizumab + Chemotherapy Initiated as Treatment for NSCLC

BeiGene, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs, has dosed the first patient dosed in a Phase III clinical trial of tislelizumab,...